Yunqi Capital's Opposition to STAAR Surgical Co Merger

Yunqi Path Capital Master Fund, Yunqi Capital Limited, Yunqi Capital Cayman Limited, and Christopher Min Fang Wang (collectively, the 'Reporting Persons') have filed a Schedule 13D regarding their investment in STAAR Surgical Co. The Reporting Persons hold 2,500,061 shares, representing 5.1% of the company's common stock. They have announced their intention to vote against the proposed merger with Alcon, citing concerns over the merger process, the Issuer's assessment of the macroeconomic climate in China, and the belief that the merger significantly undervalues STAAR Surgical Co. The Reporting Persons may explore strategic alternatives to the merger and intend to review their investment in the company on a continuing basis.